TY - JOUR
T1 - Subtypes of familial breast tumours revealed by expression and copy number profiling
AU - Waddell, Nic
AU - Arnold, Jeremy
AU - Cocciardi, Sibylle
AU - Da Silva, Leonard
AU - Marsh, Anna
AU - Riley, Joan
AU - Johnstone, Cameron N.
AU - Orloff, Mohammed
AU - Assie, Guillaume
AU - Eng, Charis
AU - Reid, Lynne
AU - Keith, Patricia
AU - Yan, Max
AU - Fox, Stephen
AU - Devilee, Peter
AU - Godwin, Andrew K.
AU - Hogervorst, Frans B.L.
AU - Couch, Fergus
AU - Investigators, Kconfab
AU - Grimmond, Sean
AU - Flanagan, James M.
AU - Khanna, Kumkum
AU - Simpson, Peter T.
AU - Lakhani, Sunil R.
AU - Chenevix-Trench, Georgia
N1 - Funding Information:
Acknowledgements We wish to thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded by NHMRC grants 145684, 288704 and 454508) for their contributions to this resource, and the many families who contributed to kConFab. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. GCT and KKK are NHMRC Research Fellows. CE holds the Sondra J. and Stephen R. Hardis Chair of Cancer Genomic Medicine at the Cleveland Clinic, is a Doris Duke Distinguished Clinical Scientist and an American Cancer Society Clinical Research Professor. We also wish to thank Jelle Wesseling, pathologist, and Petra Kristel, technician, for helping with the selection of BRCA2 tumours from the Netherlands Cancer Institute. This study was supported by grants from the National Breast Cancer Foundation and the NHMRC.
PY - 2010/10
Y1 - 2010/10
N2 - Extensive expression profiling studies have shown that sporadic breast cancer is composed of five clinically relevant molecular subtypes. However, although BRCA1-related tumours are known to be predominantly basal-like, there are few published data on other classes of familial breast tumours. We analysed a cohort of 75 BRCA1, BRCA2 and non-BRCA1/2 breast tumours by gene expression profiling and found that 74% BRCA1 tumours were basal-like, 73% of BRCA2 tumours were luminal A or B, and 52% non-BRCA1/2 tumours were luminal A. Thirtyfour tumours were also analysed by single nucleotide polymorphism-comparative genomic hybridization (SNPCGH) arrays. Copy number data could predict whether a tumour was basal-like or luminal with high accuracy, but could not predict its mutation class. Basal-like BRCA1 and basal-like non-BRCA1 tumours were very similar, and contained the highest number of chromosome aberrations. We identified regions of frequent gain containing potential driver genes in the basal (8q and 12p) and luminal A tumours (1q and 17q). Regions of homozygous loss associated with decreased expression of potential tumour suppressor genes were also detected, including in basal tumours (5q and 9p), and basal and luminal tumours (10q). This study highlights the heterogeneity of familial tumours and the clinical consequences for treatment and prognosis.
AB - Extensive expression profiling studies have shown that sporadic breast cancer is composed of five clinically relevant molecular subtypes. However, although BRCA1-related tumours are known to be predominantly basal-like, there are few published data on other classes of familial breast tumours. We analysed a cohort of 75 BRCA1, BRCA2 and non-BRCA1/2 breast tumours by gene expression profiling and found that 74% BRCA1 tumours were basal-like, 73% of BRCA2 tumours were luminal A or B, and 52% non-BRCA1/2 tumours were luminal A. Thirtyfour tumours were also analysed by single nucleotide polymorphism-comparative genomic hybridization (SNPCGH) arrays. Copy number data could predict whether a tumour was basal-like or luminal with high accuracy, but could not predict its mutation class. Basal-like BRCA1 and basal-like non-BRCA1 tumours were very similar, and contained the highest number of chromosome aberrations. We identified regions of frequent gain containing potential driver genes in the basal (8q and 12p) and luminal A tumours (1q and 17q). Regions of homozygous loss associated with decreased expression of potential tumour suppressor genes were also detected, including in basal tumours (5q and 9p), and basal and luminal tumours (10q). This study highlights the heterogeneity of familial tumours and the clinical consequences for treatment and prognosis.
KW - BRCA1 and BRCA2
KW - Copy number aberrations
KW - Familial breast cancer
KW - Gene expression
KW - Molecular subtypes
UR - http://www.scopus.com/inward/record.url?scp=79952118064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952118064&partnerID=8YFLogxK
U2 - 10.1007/s10549-009-0653-1
DO - 10.1007/s10549-009-0653-1
M3 - Article
C2 - 19960244
AN - SCOPUS:79952118064
SN - 0167-6806
VL - 123
SP - 661
EP - 677
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -